(Bloomberg) – House Democrats want to know how Gilead Sciences Inc. set the $84,000 price for a standard course of treatment with Solvadi, a new hepatitis C drug.
The lawmakers also asked Gilead Chief Executive Officer John Martin to explain what is being done to make sure the medicine gets into the hands of low-income patients, especially in government-run health programs.
Copyright 2016 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.